ASH 65th Annual Meeting & Exposition: Friday Satellite Symposia

Medical Crossfire: Novel BTKi Strategies Transforming Aggressive and Indolent B-Cell Malignancies

This program is supported by Lilly, Merck and Co., Inc., Pharmacyclics LLC, an AbbVie Company’s and Janssen Biotech, Inc.

7:00 a.m. - 10:00 a.m. Pacific time

San Diego Convention Center
Room 6B

Access Program Details

The rapid pace and sheer volume of basic science and therapeutic developments that continue to emerge in the field of BTK inhibitors creates practice and/or educational gaps, particularly for hematology-oncologists and oncology nurses who strive to deliver the best possible care to patients. This Medical Crossfire® will provide an ideal format for the lymphoma care team to participate in an open exchange of ideas and viewpoints fostered by a case-based agenda allowing them to review patient scenarios, reflect on how they might handle particular cases, integrate relevant evidence into real-world practice, and compare their patient care approaches with those of experts and peers. Faculty leading discussion of common clinical scenarios and solutions will discuss methods to best integrate the latest therapies into B-cell lymphoma treatment paradigms, address barriers to optimized integration of these novel agents, as well provide best practices for the management of adverse events.


Ian W. Flinn, MD, PhD
Sarah Cannon Research Institute and Tennessee Oncology
Nashville, TN


Catherine C. Coombs, MD
University of California Irvine
Irvine, CA

Paolo Strati, MD
The University of Texas MD Anderson Cancer Center
Houston, TX

Steven P. Treon, MD, PhD, FRCP
Dana-Farber Cancer Institute
Boston, MA

Michael Wang, MD
The University of Texas MD Anderson Cancer Center
Houston, TX

Kelly Donald , Physicians Education Resources, LLC